Appendix II — G — Decisions Cited — G
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
G, In re Application of, 11 USPQ2d 1378 (Comm’r Pat. 1989) 711.03(c)
Gallo, In re, 231 USPQ 496 (Comm’r Pat. 1986) 103
Gambro Lundia AB v. Baxter Healthcare Corp., 110 F.3d 1573, 42 USPQ2d 1378 (Fed. Cir. 1997) 2137
Gandy v. Main Belting Co., 143 U.S. 587 (1892) 2133.03(d)
Garbo, In re, 287 F.2d 192, 129 USPQ 72 (CCPA 1961) 1504.03
Gardner, In re, 427 F.2d 786, 166 USPQ 138 (CCPA 1970) 2173.04 , 2173.05(h)
Gardner, In re, 475 F.2d 1389, 177 USPQ 396 (CCPA 1973) 601.01(d) , 2107.01 , 2107.03 , 2163
Gardner v. TEC Systems, Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984) 2144.04
Garfinkel, In re, 437 F.2d 1000, 168 USPQ 659 (CCPA 1971) 715
Garnero, In re, 412 F.2d 276, 162 USPQ 221 (CCPA 1979) 2113
Garret Corp. v. United States, 422 F.2d 874, 164 USPQ 521 (Ct. Cl. 1970) 2128.01
Gartside, In re, 203 F.3d 1305, 53 USPQ2d 1769 (Fed. Cir. 2000) 2144.03
Gaubert, In re, 524 F.2d 1222, 187 USPQ 664 (CCPA 1975) 2107.02 , 2107.03 , 2173.05(h)
Gaubert, In re, 530 F.2d 1402, 189 USPQ 432 (CCPA 1975) 2107.02 , 2107.03
Gay, In re, 309 F.2d 769, 135 USPQ 311 (CCPA 1962) 608.01(h) , 2161.01 , 2165.01
Gazave, In re, 379 F.2d 973, 154 USPQ 92 (CCPA 1967) 2107.01 , 2107.02 , 2107.03 , 2164.07
Gazda, In re, 219 F.2d 449, 104 USPQ 400 (CCPA 1955) 2144.04
Gearon v. United States, 121 F. Supp. 652, 101 USPQ 460 (Ct. Cl. 1954) 601.01(e)
Gebauer-Fuelnegg, In re, 121 F.2d 505, 50 USPQ 125 (CCPA 1941) 608.01(v)
Geiger, In re, 815 F.2d 686, 2 USPQ2d 1276 (Fed. Cir. 1987) 716.02(e) , 2144.06
G.D. Searle LLC v. Lupin Pharm., Inc., 790 F.3d 1349, 115 USPQ2d 1326 (Fed. Cir. 2015) 804.01 , 1402 , 1481.03
Geisler, In re, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997) 2144.05 , 2145
Gellert v. Wanberg, 495 F.2d 779, 181 USPQ 648 (CCPA 1974) 2138.05
Gelles, Ex parte, 22 USPQ2d 1318 (Bd. Pat. App. & Inter. 1992) 716.02 , 716.02(b)
Gemveto Jewelry Co. v. Lambert Bros., Inc., 542 F. Supp. 933, 216 USPQ 976 (S.D. N.Y. 1982) 2001.06(a) , 2004 , 2016
Genentech, Inc. v. Chiron Corp., 112 F.3d 495, 42 USPQ2d 1608 (Fed. Cir. 1997) 2111.03 , 2163
Genentech, Inc. v. Chiron Corp., 220 F.3d 1345, 55 USPQ2d 1636 (Fed. Cir. 2000) 2138.05
Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 42 USPQ2d 1001 (Fed. Cir. 1997) 2161.01
Genentech v. Wellcome Foundation, 29 F.3d 1555, 31 USPQ2d 1161 (Fed. Cir. 1994) 2164.04
General Electric Co., In re, 789 F. App’x 857, 2019 USPQ2d 399054 (Fed. Cir. 2019) 1412.01 , 1412.02
General Electric Co. v. Brenner, 407 F.2d 1258, 159 USPQ 335 (D.C. Cir. 1968) 608.01(p)
General Elec. v. United States, 206 USPQ 260 (Ct. Cl. 1979) 2133.03(e)(1)
General Elec. Co. v. Wabash Appliance Corp., 304 U.S. 364, 37 USPQ 466 (1938) 2173.05(g)
General Electro Music Corp. v. Samick Music Corp., 19 F.3d 1405, 30 USPQ2d 1149 (Fed. Cir. 1994) 410
General Foods Corp. v. Studiengesellschaft Kohle mbH, 972 F.2d 1272, 23 USPQ2d 1839 (Fed. Cir. 1992) 804
General Hosp. Corp. v. Sienna Biopharmaceuticals, Inc., 888 F.3d 1368, 126 USPQ2d 1556 (Fed. Cir. 2018) 2163.05
General Motors Corp. v. Bendix Aviation Corp., 123 F. Supp 506, 102 USPQ 58 (N.D. Ind. 1954) 2133.03(e)(6)
Genetic Techs. Ltd. v. Merial LLC, 818 F.3d 1369, 118 USPQ2d 1541 (Fed. Cir. 2016) 2106 , 2106.04(b) , 2106.05 , 2106.05(d) , 2106.05(h) , 2106.07(a)
Genetics Institute LLC v. Novartis Vaccines and Diagnostics Inc., 655 F.3d 1291, 99 USPQ2d 1713 (Fed. Cir. 2011) 2750
Geneva Pharms. Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373, 68 USPQ2d 1865 (Fed. Cir. 2003) 804 , 804.01 , 804.02 , 804.04 , 814 , 1504.06
Gentry Gallery, Inc. v. Berkline Corp., 134 F.3d 1473, 45 USPQ2d 1498 (Fed. Cir. 1998) 2163 , 2163.05 , 2172.01
George, Ex parte, 21 USPQ2d 1058 (Bd. Pat. App. & Inter. 1991) 716.01(c)
George, In re, 2 USPQ2d 1880 (Bd. Pat. App. & Inter. 1987) 2128.01
Gerber Garment Technology, Inc. v. Lectra Systems, Inc., 916 F.2d 683, 16 USPQ2d 1436 (Fed. Cir. 1990) 804.01 , 804.02 , 804.04
Gershon, In re, 372 F.2d 535, 152 USPQ 602 (CCPA 1967) 716.02(c) , 716.04
Ghiron, In re, 442 F.2d 985, 169 USPQ 723 (CCPA 1971) 2161.01 , 2164.06(a) , 2164.01(b) , 2164.06(c) , 2164.06 , 2164.06(a) , 2185
Ghuman, Ex parte, 88 USPQ2d 1478, 2008 WL 2109842 (BPAI 2008) 1205.02
Giannelli, In re, 739 F.3d 1375, 109 USPQ2d 1333 (Fed. Cir. 2014) 2111.04
Gibbs, In re, 437 F.2d 486, 168 USPQ 578 (CCPA 1971) 2134
Gibson, Ex parte, 20 USPQ 249 (Bd. App. 1933) 1504.01(b)
Gibson, In re, 39 F.2d 975, 5 USPQ 230 (CCPA 1930) 2144.04
Gilead Sciences Inc. v. Lee, 778 F.3d 1341, 113 USPQ2d 1837 (Fed. Cir. 2015) 2732
Gilead Sciences, Inc. v. Natco Pharma Ltd., 753 F.3d 1208, 110 USPQ2d 1551 (Fed. Cir. 2014) 804
Gillette Co. v. Energizer Holdings Inc., 405 F.3d 1367, 74 USPQ2d 1586 (Fed. Cir. 2005) 2111.03
Gillman v. Stern, 114 F.2d 28, 46 USPQ 430 (2d Cir. 1940) 2133.03(a)
Ginos v. Nedelec, 220 USPQ 831 (Bd. Pat. Inter. 1983) 2138.05 , 2138.06
Glaser v. Strickland, 220 USPQ 446 (Bd. Pat. Inter. 1983) 716.09
Glass, In re, 492 F.2d 1228, 181 USPQ 31 (CCPA 1974) 608.01(h) , 608.01(p) , 2124 , 2165.02
Glavas, In re, 230 F.2d 447, 109 USPQ 50 (CCPA 1956) 1504.03
Glaxo Inc. v. Novopharm Ltd., 52 F.3d 1043, 34 USPQ2d 1565 (Fed. Cir. 1995) 2107.01
Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp. 1224, 10 USPQ2d 1100 (E.D. Va. 1989) 2751
Gleave, In re, 560 F.3d 1331, 90 USPQ2d 1235 (Fed. Cir. 2009) 2152.02(b)
Goffe, In re, 542 F.2d 564, 191 USPQ 429 (CCPA 1976) 2164.08 , 2164.08(c) , 2172.01
Golden Valley Microwave Food Inc. v. Weaver Popcorn Co., 837 F. Supp. 1444, 24 USPQ2d 1801 (N.D. Ind. 1992) 410
Goldgaber, Ex parte, 41 USPQ2d 1172 (Bd. Pat. App. & Inter. 1996) 2144.09
Goldstein, In re, 16 USPQ2d 1963 (Dep. Assist. Comm’r Pat. 1988) 402.10
Golight Inc. v. Wal-Mart Stores Inc., 355 F.3d 1327, 69 USPQ2d 1481 (Fed. Cir. 2004) 2182
Good, Ex parte, 1911 C.D. 43, 164 O.G. 789 (Comm’r Pat. 1911) 608.02(d)
Goodman, In re, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993) 804 , 806.04(i) , 1504.06 , 2164.06(b) , 2164.08
Goodyear Tire & Rubber Co., Ex parte, 230 USPQ 357 (Bd. Pat. App. & Inter. 1985) 2141.01(a)
GoPro, Inc. v. Contour IP Holding LLC, 908 F.3d 690, 128 USPQ2d 1447 (Fed. Cir. 2018) 2128
Gordon, In re, 733 F.2d 900, 221 USPQ 1125 (Fed. Cir. 1984) 2143.01 , 2144.08
Gorham Manufacturing Co. v. White, 81 U.S. (14 Wall.) 511 (1871) 1504.01(c) , 1504.01(d) , 1504.02
Gorman, In re, 933 F.2d 982, 18 USPQ2d 1885 (Fed. Cir. 1991) 707.07(f) , 2145
Gosteli, In re, 872 F.2d 1008, 10 USPQ2d 1614 (Fed. Cir. 1989) 608.01(p) , 715.03 , 2131.02 , 2136.05 , 2163.02 , 2163.03 , 2163.05
Gottlieb, In re, 328 F.2d 1016, 140 USPQ 665 (CCPA 1964) 2107.02
Gottschalk v. Benson, 409 U.S. 63, 175 USPQ 673 (1972) 2106 , 2106.03 , 2106.04 , 2106.04(a)(1) , 2106.05(c) , 2106.05(f)
Gould v. Quigg, 822 F.2d 1074, 3 USPQ2d 1302 (Fed. Cir. 1987) 2164.02 , 2164.05(a)
Gould v. Schawlow, 363 F.2d 908, 150 USPQ 634 (CCPA 1966) 2138.06
GPAC, In re, 57 F.3d 1573, 35 USPQ2d 1116 (Fed. Cir. 1995) 716.03 , 2141 , 2141.03 , 2145
Grabiak, In re, 769 F.2d 729, 226 USPQ 871 (Fed. Cir. 1985) 2144.08 , 2144.09
Grady, Ex parte, 59 USPQ2d 276 (Comm’r Pat. 1943) 607.02
Graff, In re, 111 F.3d 874, 42 USPQ2d 1471 (Fed. Cir. 1997) 1403 , 1412.03 , 1451
Graham v. John Deere, 383 U.S. 1, 148 USPQ 459 (1966) 716.01(a) , 804 , 1504.03 , 1504.06 , 2141 , 2142 , 2144.08 , 2145 , 2148 , 2158 , 2158.01 , 2258
Gramme Elec. Co. v. Arnoux and Hochhausen Elec. Co., 17 F. 838, 1883 C.D. 418 (S.D. N.Y. 1883) 2135.01
Grams, In re, 888 F.2d 835, 12USPQ2d 1824 (Fed. Cir. 1989) 2106.04(a)(1) , 2106.05(g)
Grant v. Raymond, 31 U.S. 218 (1832) 1440
Grasselli, Ex parte, 231 USPQ 393 (Bd. App. 1983) 2143.03 , 2173.05(i)
Grasselli, In re, 713 F.2d 731, 218 USPQ 769 (Fed. Cir. 1983) 716.02(d) , 2112 , 2145
Graver Tank & Mfg. Co. v. Linde Air Products, 339 U.S. 605, 85 USPQ 328 (1950) 2183 , 2184 , 2186
Gray, Ex parte, 10 USPQ2d 1922 (Bd. Pat. App. & Inter. 1989) 716.01(c) , 2113
Gray, In re, 115 USPQ 80 (Comm’r Pat. 1956) 409.03(d) , 409.03(f)
Gray, In re, 53 F.2d 520, 11 USPQ 255 (CCPA 1931) 2111.03
Great Atlantic & P. Tea Co. v. Supermarket Equipment Corp., 340 U.S. 147, 87 USPQ 303 (1950) 716.01(a) , 2143 , 2143.01
Green v. The Rich Iron Co., 944 F.2d 852, 20 USPQ2d 1075 (Fed. Cir. 1991) 1442.05
Greenberg v. Ethicon Endo-Surgery, Inc., 91 F.3d 1580, 39 USPQ2d 1783 (Fed. Cir. 1996) 2181
Greenewalt v. Stanley, 54 F.2d 195, 12 USPQ 122 (3d Cir. 1931) 2133.03(e)(1)
Greenfield, In re, 40 F.2d 775, 5 USPQ 474 (CCPA 1930) 1214.01
Greenfield, In re, 571 F.2d 1185, 197 USPQ 227 (CCPA 1978) 2145
Greenliant Systems, Inc. v. Xicor LLC, 692 F.3d 1261, 103 USPQ2d 1951 (Fed. Cir. 2012) 1412.02
Greenwood v. Seiko Instruments, 8 USPQ2d 1455 (D.D.C. 1988) 2273
Greer, In re, 484 F.2d 488, 179 USPQ 301 (CCPA 1973) 1605
Griffin v. Bertina, 285 F.3d 1029, 62 USPQ2d 1431 (Fed. Cir. 2002) 2103 , 2111.04 , 2143.03
Griffith v. Kanamaru, 816 F.2d 624, 2 USPQ2d 1361 (Fed. Cir. 1987) 2138.06
Griswold, In re, 365 F.2d 834, 150 USPQ 804 (CCPA 1966) 804.02
Grose, In re, 592 F.2d 1161, 201 USPQ 57 (CCPA 1979) 2144.02 , 2144.03 , 2145
Group One, Ltd. v. Hallmark Cards, Inc., 254 F.3d 1041, 59 USPQ2d 1121 (Fed. Cir. 2001) 2133.03(b) , 2152.02(e)
Grunwell, In re, 609 F.2d 486, 203 USPQ 1055 (CCPA 1979) 2107.02
GS Cleantech Corp. v. Adkins Energy LLC, 951 F.3d 1310, 2020 USPQ2d 10092 (Fed. Cir. 2020) 2004
Guastavino, In re, 83 F.2d 913, 29 USPQ 532 (CCPA 1936) 1449.02
Gulack, In re, 703 F.2d 1381, 217 USPQ 401 (Fed. Cir. 1983) 2111.05 , 2112.01 , 2143.03
Gulliksen v. Halberg, 75 USPQ 252 (Bd. App. 1937) 2128.01
Gunn, In re, 537 F.2d 1123, 190 USPQ 402 (CCPA 1976) 2164.05(a) , 2164.06 , 2164.06(a) , 2164.06(c)
Gunn v. Bosch, 181 USPQ 758 (Bd. Pat. Inter. 1973) 2138.06
Gunter v. Stream, 573 F.2d 77, 197 USPQ 482 (CCPA 1978) 2138.04
Gurley, In re, 27 F.3d 551, 31 USPQ2d 1130 (Fed. Cir. 1994) 2123 , 2145
Gustafson, In re, 331 F.2d 905, 141 USPQ 585 (CCPA 1964) 2173.05(k)
Gustafson v. Strange, 227 USPQ 174 (Comm’r Pat. 1985) 513
Gwinn, Ex parte, 112 USPQ 439 (Bd. App. 1955) 2111.05
Cited authority
- 711.03(c) Petitions Relating to Abandonment
- 103 Right of Public To Inspect Patent Files and Some Application Files
- 2137 Pre-AIA 35 U.S.C. 102(f)
- 2133.03(d) “In This Country”
- 1504.03 Nonobviousness
- 2173.04 Breadth Is Not Indefiniteness
- 2173.05(h) Alternative Limitations
- 601.01(d) Application Filed Without All Pages of Specification
- 2107.01 General Principles Governing Utility Rejections
- 2107.03 Special Considerations for Asserted Therapeutic or Pharmacological Utilities
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 2144.04 Legal Precedent as Source of Supporting Rationale
- 715 Swearing Behind a Reference — Affidavit or Declaration Under 37 CFR 1.131(a)
- 2113 Product-by-Process Claims
- 2128.01 Level of Public Accessibility Required
- 2144.03 Reliance on Common Knowledge in the Art or “Well Known” Prior Art
- 2107.02 Procedural Considerations Related to Rejections for Lack of Utility
- 608.01(h) Mode of Operation of Invention
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2165.01 Considerations Relevant to Best Mode
- 2164.07 Relationship of Enablement Requirement to Utility Requirement of 35 U.S.C. 101
- 601.01(e) Nonprovisional Application Filed Without at Least One Claim
- 608.01(v) Marks Used in Commerce and Trade Names
- 716.02(e) Comparison With Closest Prior Art
- 2144.06 Art Recognized Equivalence for the Same Purpose
- 804.01 Prohibition of Nonstatutory Double Patenting Rejections Under 35 U.S.C. 121
- 1402 Grounds for Filing
- 1481.03 Correction of 35 U.S.C. 119 and 35 U.S.C. 120 Benefits
- 2144.05 Obviousness of Similar and Overlapping Ranges, Amounts, and Proportions
- 2145 Consideration of Applicant’s Rebuttal Arguments and Evidence
- 2138.05 “Reduction to Practice”
- 716.02 Allegations of Unexpected Results
- 716.02(b) Burden on Applicant
- 2001.06(a) Prior Art Cited in Related Foreign Applications
- 2004 Aids to Compliance With Duty of Disclosure
- 2016 Fraud, Inequitable Conduct, or Violation of Duty of Disclosure Affects All Claims
- 2111.03 Transitional Phrases
- 2164.04 Burden on the Examiner Under the Enablement Requirement
- 1412.01 Reissue Claims Must Be for Same General Invention
- 1412.02 Recapture of Canceled Subject Matter
- 608.01(p) Completeness of Specification
- 2133.03(e)(1) Commercial Exploitation
- 2173.05(g) Functional Limitations
- 410 Representations to the U.S. Patent and Trademark Office
- 804 Definition of Double Patenting
- 2163.05 Changes to the Scope of Claims
- 2133.03(e)(6) Permitted Experimental Activity and Testing
- 2106 Patent Subject Matter Eligibility
- 2106.04(b) Laws of Nature, Natural Phenomena & Products of Nature
- 2106.05 Eligibility Step 2B: Whether a Claim Amounts to Significantly More
- 2106.05(d) Well-Understood, Routine, Conventional Activity
- 2106.05(h) Field of Use and Technological Environment
- 2106.07(a) Formulating a Rejection For Lack of Subject Matter Eligibility
- 2750 Patent Term Extension for Delays at other Agencies under 35 U.S.C. 156
- 804.02 Avoiding a Double Patenting Rejection
- 804.04 Submission to Technology Center Director
- 814 Indicate Exactly How Application Is To Be Restricted
- 1504.06 Double Patenting
- 2172.01 Unclaimed Essential Subject Matter
- 716.01(c) Probative Value of Objective Evidence
- 716.02(c) Weighing Evidence of Expected and Unexpected Results
- 716.04 Long-Felt Need and Failure of Others
- 2164.06(a) Examples of Enablement Issues-Missing Information
- 2164.01(b) How to Make the Claimed Invention
- 2164.06(c) Examples of Enablement Issues – Computer Programming Cases
- 2164.06 Quantity of Experimentation
- 2185 Related Issues Under 35 U.S.C. 112(a) or (b) and Pre-AIA 35 U.S.C. 112, First or Second Paragraphs
- 1205.02 Appeal Brief Content
- 2111.04 “Adapted to,” “Adapted for,” “Wherein,” “Whereby,” and Contingent Clauses
- 2134 Pre-AIA 35 U.S.C. 102(c)
- 1504.01(b) Design Comprising Multiple Articles or Multiple Parts Embodied in a Single Article
- 2732 Reduction of Period of Adjustment of Patent Term
- 2133.03(a) “Public Use”
- 2138.06 “Reasonable Diligence”
- 716.09 Sufficiency of Disclosure
- 2124 Exception to the Rule That the Reference Must be Prior Art
- 2165.02 Best Mode Requirement Compared to Enablement Requirement
- 2751 Eligibility Requirements
- 2152.02(b) Described in a Printed Publication
- 2164.08 Enablement Commensurate in Scope With the Claims
- 2164.08(c) Critical Feature Not Claimed
- 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers)
- 402.10 Appointment/Revocation by Less Than All Applicants or Owners
- 2182 Search and Identification of the Prior Art
- 608.02(d) Complete Illustration in Drawings
- 806.04(i) Generic Claims Presented In a Separate Application After Issuance of Species Claims
- 2164.06(b) Examples of Enablement Issues — Biological and Chemical Cases
- 2141.01(a) Analogous and Nonanalogous Art
- 2128 “Printed Publications” as Prior Art
- 2143.01 Suggestion or Motivation To Modify the References
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 1504.01(c) Lack of Ornamentality
- 1504.01(d) Simulation
- 1504.02 Novelty
- 707.07(f) Answer All Material Traversed
- 715.03 Genus-Species, Practice Relative to Cases Where Predictability Is in Question
- 2131.02 Genus-Species Situations
- 2136.05 Overcoming a Rejection Under Pre-AIA 35 U.S.C. 102(e)
- 2163.02 Standard for Determining Compliance With the Written Description Requirement
- 2163.03 Typical Circumstances Where Adequate Written Description Issue Arises
- 2106.03 Eligibility Step 1: The Four Categories of Statutory Subject Matter
- 2106.04 Eligibility Step 2A: Whether a Claim is Directed to a Judicial Exception
- 2106.04(a)(2) Abstract Idea Groupings
- 2106.05(c) Particular Transformation
- 2106.05(f) Mere Instructions To Apply An Exception
- 2164.02 Working and Prophetic Examples
- 2164.05(a) Specification Must Be Enabling as of the Filing Date
- 716.03 Commercial Success
- 2141 Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103
- 2141.03 Level of Ordinary Skill in the Art
- 607.02 Returnability of Fees
- 1403 Diligence in Filing
- 1412.03 Broadening Reissue Claims
- 1451 Divisional Reissue Applications; Continuation Reissue Applications Where the Parent is Pending
- 716.01(a) Objective Evidence of Nonobviousness
- 2142 Legal Concept of Prima Facie Obviousness
- 2148 Form Paragraphs for Use in Rejections Under Pre-AIA 35 U.S.C. 103
- 2158 AIA 35 U.S.C. 103
- 2158.01 Form Paragraphs for Use in Rejections Under AIA 35 U.S.C. 103
- 2258 Scope of Ex Parte Reexamination
- 2135.01 The Four Requirements of Pre-AIA 35 U.S.C. 102(d)
- 2106.05(g) Insignificant Extra-Solution Activity
- 1440 Examination of Reissue Application
- 2143.03 All Claim Limitations Must Be Considered
- 2173.05(i) Negative Limitations
- 716.02(d) Unexpected Results Commensurate in Scope With Claimed Invention
- 2112 Requirements of Rejection Based on Inherency; Burden of Proof
- 2183 Making a Prima Facie Case of Equivalence
- 2184 Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made
- 2186 Relationship to the Doctrine of Equivalents
- 409.03(d) Proof of Unavailability or Refusal
- 409.03(f) Proof of Proprietary Interest
- 2143 Examples of Basic Requirements of a Prima Facie Case of Obviousness
- 1442.05 Court Ordered Filing of Reissue Application
- 2181 Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation
- 1214.01 Procedure Following New Ground of Rejection by Board
- 2273 Appeal in Ex Parte Reexamination
- 1605 Specification and Claim
- 2103 Patent Examination Process
- 2144.02 Reliance on Scientific Theory
- 2133.03(b) “On Sale”
- 2152.02(e) Otherwise Available to the Public
- 1449.02 Interference in Reissue
- 2111.05 Functional and Nonfunctional Descriptive Material
- 2112.01 Composition, Product, and Apparatus Claims
- 2138.04 “Conception”
- 2123 Rejection Over Prior Art’s Broad Disclosure Instead of Preferred Embodiments
- 2173.05(k) Aggregation
- 513 Deposit as Priority Mail Express® with U.S. Postal Service